Curriculum Vitae – Dr. Annemie Narkus
License to practice | |
01.08.1988 | License to practice medicine granted after studies in Düsseldorf and Göttingen |
Doctorate | |
07.06.1994 | Doctorate with Prof. Schultze-Werninghaus at Ruhr-University Bochum Topic: Prevalence and clinical significance of storage mites as a cause of exogenous allergic asthma in an unselected patient population and in farmers in Northern Germany |
Experience | |
10/1988 –12/1989 | Fa. Byk Gulden Konstanz – Pharmaceutical representative |
01/1990–09/1991 | Allergopharma Reinbek – Physician in clinical research on allergies |
10/1991-06/2001 | GlaxoSmithKline – Physician in the area of medicine and research in various positions: |
since 10/1991 | Medical Advisor Respiratory |
since 05/1994 | Senior Medical Advisor – medical-scientific responsibility for all therapeutic agents for respiratory diseases |
since 08/1995 | Deputy department head of the entire medical affairs department |
since 05/1996 | Head of clinical research with responsibility for international and national clinical trials phases I-IV, as well as post-marketing surveillance studies in the indication areas: Respiratory, anti-infective, CNS, gastrointestinal, HIV, anesthesia, diabetes, cardiovascular and intensive medicine. |
since 1997 | Also head of biometrics and data management with total of approx.55 employees |
since 10/1998 | Therapeutic Area Director Respiratory/Antibiotics – Set-up of a new department with medical-strategic responsibility for the entire respiratory and antibiotic range with a sales volume of approx. 400 million as well as the corresponding pipeline products. Also information officer. |
since 05/1998 | Also Deputy Director Research & Medicine for all indications.
Also head of several working groups in the context of the diagnostic and re-design phases of the restructuring and integration teams, as part of the Wellcome, Cascan and GlaxoSmithKline integration. The best product launches: Viani®/Seretide® (combination product of inhaled corticosteroid and long-acting β2-agonist) – launch in April 1999 was the best launch in GlaxoWellcome’s history. Two years after launching the product, despite a very competitive field, aimed to achieve a sales volume in Germany alone of DM 200 million |
from 7/2001- present | Chief Executive Officer (CEO) at MC GmbH:
Collaboration with GlaxoSmithKline since 2001. Medical Director/Vice-President Clinical Development & Regulatory Affairs for all allergy diagnostics and therapeutic agents at Allergopharma from 03/2003 – 12/2014 with the departments: Collaboration with various CROs and other companies specializing in allergies and respiratory diseases. |